Tofacitinib efficacy, patient-reported outcomes and safety in patients with psoriasis and a medical history of psoriatic arthritis: Pooled analysis of two Phase III studies

被引：4

作者：

Bachelez, H. ^{[1
,2
]}

Griffiths, C. E. M. ^{[3
,4
]}

Papp, K. A. ^{[5
,6
]}

Hall, S. ^{[7
]}

Merola, J. F. ^{[8
]}

Feldman, S. R. ^{[9
]}

Khraishi, M. ^{[10
]}

Tan, H. ^{[11
]}

Fallon, L. ^{[12
]}

Cappelleri, J. C. ^{[11
]}

Bushmakin, A. G. ^{[11
]}

Young, P. ^{[13
]}

机构：

[1] Hop St Louis, AP HP, Dept Dermatol, Paris, France

[2] Univ Paris, Imagine Inst, Unite INSERM U1163, Paris, France

[3] Univ Manchester, NIHR Manchester Biomed Res Ctr, Salford Royal Hosp, Dermatol Ctr, Manchester, England

[4] Kings Coll Hosp London, Kings Coll London, Dept Dermatol, London, England

[5] Prob Med Res & Alliance Clin Trials Inc, Waterloo, ON, Canada

[6] Univ Toronto, Toronto, ON, Canada

[7] Malvern, Res, Melbourne, Australia

[8] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA

[9] Wake Forest Univ, Sch Med, Winston Salem, NC USA

[10] Mem Univ Newfoundland, St John, NF, Canada

[11] Pfizer Inc, Groton, CT USA

[12] Pfizer Inc, Kirkland, PQ, Canada

[13] Pfizer Inc, 500 Arcola Rd, Collegeville, PA 19426 USA

来源：

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2024年 / 38卷 / 07期

关键词：

JANUS KINASE INHIBITOR; PLACEBO;

D O I：

10.1111/jdv.19701

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：E557 / E561

页数：5

共 12 条

[1] Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial [J].

Bachelez, Herve ;

van de Kerkhof, Peter C. M. ;

Strohal, Robert ;

Kubanov, Alexey ;

Valenzuela, Fernando ;

Lee, Joo-Heung ;

Yakusevich, Vladimir ;

Chimenti, Sergio ;

Papacharalambous, Jocelyne ;

Proulx, James ;

Gupta, Pankaj ;

Tan, Huaming ;

Tawadrous, Margaret ;

Valdez, Hernan ;

Wolk, Robert .

LANCET, 2015, 386 (9993) :552-561

[2] Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure [J].

Burmester, Gerd R. ;

Nash, Peter ;

Sands, Bruce E. ;

Papp, Kim ;

Stockert, Lori ;

Jones, Thomas, V ;

Tan, Huaming ;

Madsen, Ann ;

Valdez, Hernan ;

Cohen, Stanley B. .

RMD OPEN, 2021, 7 (02)

[3] Skin Involvement in Psoriatic Arthritis Worsens Overall Disease Activity, Patient-Reported Outcomes, and Increases Healthcare Resource Utilization: An Observational, Cross-Sectional Study [J].

de Vlam, Kurt ;

Merola, Joseph F. ;

Birt, Julie A. ;

Sandoval, David M. ;

Lobosco, Steve ;

Moon, Rachel ;

Milligan, Gary ;

Boehncke, Wolf-Henning .

RHEUMATOLOGY AND THERAPY, 2018, 5 (02) :423-436

[4] Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update [J].

DeTora, Lisa M. ;

Toroser, Dikran ;

Sykes, Angela ;

Vanderlinden, Christine ;

Plunkett, Fiona J. ;

Lane, Trevor ;

Hanekamp, Eline ;

Dormer, Laura ;

DiBiasi, Faith ;

Bridges, Dan ;

Baltzer, Lise ;

Citrome, Leslie .

ANNALS OF INTERNAL MEDICINE, 2022, 175 (09) :1298-+

[5] Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors [J].

Gladman, Dafna ;

Rigby, William ;

Azevedo, Valderilio F. ;

Behrens, Frank ;

Blanco, Ricardo ;

Kaszuba, Andrzej ;

Kudlacz, Elizabeth ;

Wang, Cunshan ;

Menon, Sujatha ;

Hendrikx, Thijs ;

Kanik, Keith S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (16) :1525-1536

[6] Psoriatic arthritis [J].

Gladman, Dafna D. .

DERMATOLOGIC THERAPY, 2009, 22 (01) :40-55

[7]

Gupta P, 2015, J INVEST DERMATOL, V135, pS8

[8] Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis [J].

Mease, P. ;

Hall, S. ;

FitzGerald, O. ;

van der Heijde, D. ;

Merola, J. F. ;

Avila-Zapata, F. ;

Cieslak, D. ;

Graham, D. ;

Wang, C. ;

Menon, S. ;

Hendrikx, T. ;

Kanik, K. S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (16) :1537-1550

[9] Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health-related quality of life from two randomized phase 3 studies [J].

Merola, J. F. ;

Papp, K. A. ;

Nash, P. ;

Gratacos, J. ;

Boehncke, W. H. ;

Thaci, D. ;

Graham, D. ;

Hsu, M-A ;

Wang, C. ;

Wu, J. ;

Young, P. .

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2020, 34 (12) :2809-2820

[10] Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials [J].

Papp, K. A. ;

Menter, M. A. ;

Abe, M. ;

Elewski, B. ;

Feldman, S. R. ;

Gottlieb, A. B. ;

Langley, R. ;

Luger, T. ;

Thaci, D. ;

Buonanno, M. ;

Gupta, P. ;

Proulx, J. ;

Lan, S. ;

Wolk, R. .

BRITISH JOURNAL OF DERMATOLOGY, 2015, 173 (04) :949-961

← 1 2 →